OR WAIT 15 SECS
MilliporeSigma will provide support to Y-mAbs for the development of its monoclonal antibody for the treatment of pediatric brain cancer.
On August 1, 2016, MilliporeSigma announced that it will provide Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of the company’s monoclonal antibody (mAb) in late-stage clinical development. According to MilliporeSigma, the antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric brain cancer patients.
Thomas Gad, Y-mAbs' founder, president, and head of Business Development and Strategy, noted in a press release, "We expect to take delivery of cGMP drug product for our planned clinical trials by first half of 2017, and we are committed to making this leading immunotherapy product available to patients with life-threatening diseases worldwide."
MilliporeSigma's Provantage solution is a suite of products and services enabling biopharmaceutical companies to accelerate the progression of molecules into the clinic and toward commercialization. The package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification, and set-up for commercialization.